Interaction with p53 Enhances Binding of Cisplatin-modified DNA by High Mobility Group 1 Protein

Toshihiro Imamura, Hiroto Izumi, Gunji Nagatani, Tomoko Ise, Minoru Nomoto, Yukihide Iwamoto, Kimitoshi Kohno

Journal of Biological Chemistry · 2001 · 103 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

A nonhistone chromosomal protein, high mobility group (HMG) 1, is ubiquitous in higher eukaryotic cells and binds preferentially to cisplatin-modified DNA. HMG1 also functions as a coactivator of p53, a tumor suppressor protein. We investigated physical interactions between HMG1 and p53 and the influence of p53 on the ability of HMG1 to recognize damaged DNA. Using immunochemical coprecipitation, we observed binding of HMG1 and p53. Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363–376 of p53. Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53. An HMG1-specific antibody that recognized the A box of this protein also stimulated cisplatin-modified DNA binding. These data suggest that an interaction with either p53 or antibody may induce conformational change in the HMG1 A box that optimizes DNA binding by HMG1. Interaction of p53 with HMG1 after DNA damage may promote activation of specific HMG1 binding to damaged DNAin vivo and provide a molecular link between DNA damage and p53-mediated DNA repair. A nonhistone chromosomal protein, high mobility group (HMG) 1, is ubiquitous in higher eukaryotic cells and binds preferentially to cisplatin-modified DNA. HMG1 also functions as a coactivator of p53, a tumor suppressor protein. We investigated physical interactions between HMG1 and p53 and the influence of p53 on the ability of HMG1 to recognize damaged DNA. Using immunochemical coprecipitation, we observed binding of HMG1 and p53. Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363–376 of p53. Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53. An HMG1-specific antibody that recognized the A box of this protein also stimulated cisplatin-modified DNA binding. These data suggest that an interaction with either p53 or antibody may induce conformational change in the HMG1 A box that optimizes DNA binding by HMG1. Interaction of p53 with HMG1 after DNA damage may promote activation of specific HMG1 binding to damaged DNAin vivo and provide a molecular link between DNA damage and p53-mediated DNA repair. high mobility group glutathione S-transferase electrophoretic mobility shift assay The cytotoxic effect of cisplatin is believed to result from formation of covalent adducts with DNA (1Jamieson E.R. Lippard S.J. Chem. Rev. 1999; 99: 2467-2498Crossref PubMed Scopus (2620) Google Scholar). Cisplatin treatment induces a tumor suppressor protein, p53, to suppress cell proliferation through p21 induction (2Levine A.J. Cell. 1997; 88: 323-331Abstract Full Text Full Text PDF PubMed Scopus (6740) Google Scholar). Interestingly, p53 possesses 3′ to 5′ exonuclease activity (3Mummenbrauer T. Janus F. Müller B. Wiesmüller L. Deppert W. Grosse F. Cell. 1996; 85: 1089-1099Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). The recent observation that another protein, HMG1,1 can enhance p53-mediated transactivation suggests links between HMG1 and p53 in other physiologic settings (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). The p53 protein has been reported to accumulate in cisplatin-resistant cells (5Brown R. Clugston C. Burns P. Edlin A. Vasey P. Vojtesek B. Kaye S.B. Int. J. Cancer. 1993; 55: 678-684Crossref PubMed Scopus (211) Google Scholar). In addition to transactivation, p53 is involved in recognition and repair of DNA damage (5Brown R. Clugston C. Burns P. Edlin A. Vasey P. Vojtesek B. Kaye S.B. Int. J. Cancer. 1993; 55: 678-684Crossref PubMed Scopus (211) Google Scholar). HMG1 has three domains. The N-terminal domain (A box) and the central domain (B box) are positively charged and bind to DNA, whereas the acidic C-terminal domain interacts with histones (6Landsman D. Bustin M. Bioassays. 1993; 15: 539-546Crossref PubMed Scopus (238) Google Scholar). The amino acid sequences of the A and B boxes of HMG1 are homologous to a segment of about 70 amino acid residues called the HMG box. HMG1 does not bind to DNA in a sequence-specific manner; rather, it functions as an architectural protein for structuring chromatin. Notably, HMG1 binds preferentially to cisplatin-modified DNA (7Pil P.M. Lippard S.J. Science. 1992; 256: 234-237Crossref PubMed Scopus (512) Google Scholar). Yeast mutants lacking the HMG domain protein Ixr1 have been found to be significantly more resistant to cisplatin than wild type cells (8Brown S.J. Kellett P.J. Lippard S.J. Science. 1993; 261: 603-605Crossref PubMed Scopus (180) Google Scholar). On the other hand, distribution of HMG1 protein is changed after cisplatin treatment (9Chao J.C. Wan X.S. Engelsberg B.N. Rothblum L.I. Billings P.C. Biochim. Biophys. Acta. 1996; 1307: 213-219Crossref PubMed Scopus (18) Google Scholar), and HMG1 protein genes usually are up-regulated in cisplatin-resistant human cancer cells. 2K. Kohno, unpublished results. Thus, uncertainty prevails as to whether cellular levels of HMG proteins correlate with cellular resistance to cisplatin. HMG proteins enhance sequence-specific DNA binding of a variety of transcription factors, but whether these factors can modulate HMG1 binding to damaged DNA is not known. We therefore investigated the effect of p53 on the ability of HMG1 to recognize damaged DNA. MCF-7 cells were grown in Dulbecco's modified Eagle's medium (Nissui, Tokyo, Japan) supplemented with 10% fetal calf serum. Antibodies to p53 (Do-1) and Sp1 (PEP 2) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to p53 (Pab421) was purchased from Calbiochem (San Diego, CA). Anti-Thio antibody was purchased from Invitrogen (San Diego, CA). Antibodies to HMG1 and HMG2 were generated from synthetic peptides KGETKKKFKDPNAP (K plus amino acids 83–95), and KSEAGKKGPGRPTG (K plus amino acids 168–180) respectively, as described previously (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). Antibodies to HMG1 and HMG2 were purified using protein A/G-agarose (Qiagen, Hilden, Germany) (11Harlow E. Lane D. Using Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1999: 74-75Google Scholar). A full-length cDNA for human p53 was amplified from total RNA from a human epidermoid cancer lines, KB cells, by reverse transcription-polymerase chain reaction using the primer pairs 5′-CCATGGAGGAGCCGCAGTCAGATCC-3′ and 5′-GAAGTGGAGAATGTCAGTCTGAGTCAGGCCC-3′. The polymerase chain reaction product was cloned into the pGEM-T Easy vector (Promega., Madison, WI). The cDNA fragment then was gel purified after digestion withNotI and cloned into the pThioHis vector (Invitrogen) for a ThioHis fusion construct or the pGEX-4T vector (Amersham Pharmacia Biotech) for a GST fusion construct. GST-p53 deletion mutants were prepared as follows. For construction of GST-p53 N124, GST-p53 plasmid was digested with BsaAI, filled in, and self-ligated. For GST-p53 160C, GST-p53 plasmid was digested with NcoI and circularized by self-ligation. ThioHis-p53 deletion mutants were constructed from a ThioHis-p53 plasmid by digestion withAccI for N376, BanII for N362, and Eco81I for 224C. Plasmids for GST-HMG1 and GST-Y box-binding protein 1 were described previously (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). GST-HMG1 deletion mutants were prepared as follows. For construction of GST-HMG1ΔA and GST-HMG1ΔB,StuI-NotI and BamHI fragments of GST-HMG1 were cloned into a pGEX-4T vector, respectively. For metabolic labeling, MCF-7 cells in a 100-mm tissue culture dish were cultured with in Dulbecco's methionine and cysteine free modified Eagle's medium (Life Technologies, Inc.) supplemented with 5% dialyzed fetal calf serum and were labeled with 50 μCi/ml of [35S]methionine and cysteine labeling mixture (Amersham Pharmacia Biotech) (12Sefton M.B. Beemon K. Hunter T. J. Virol. 1978; 28: 957-971Crossref PubMed Google Scholar) with or without 20 μm cisplatin (Sigma) for 24 h. After washing the cells twice with ice-cold phosphate-buffered saline, the nuclear fraction was obtained as described previously (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar) and then was eluted with buffer containing 20 mm HEPES, pH 7.9, 0.4 m NaCl, 1 mmEDTA, 1 mm EGTA, 1 mm phenylmethylsulfonyl fluoride, and 1 mm dithiothreitol, after which the NaCl concentration of the nuclear fraction was changed to 120 mmby adding the same buffer without NaCl. GST fusion proteins were induced by isopropyl-1-thio-β-d-galactopyranoside as described previously (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). GST fusion proteins binding to 15 μl of glutathione-Sepharose 4B in a 50% slurry were mixed with 0.25 mg of35S-labeled nuclear extract from MCF-7 cells treated with or without cisplatin. The mixtures were incubated for 2 h at 4 °C and washed three times with binding buffer. Pull-down samples representing 1% of input were electrophoresed and autoradiography. MCF-7 cells growing in 100-mm tissue culture dishes were treated with 20 μm cisplatin (Sigma) for 24 h. The nuclear fraction was obtained as described above. Tubes containing the nuclear fraction were incubated for 2 h at 4 °C with 20 μl of protein A/G-agarose. Then 10 μl of preimmune rabbit IgG, anti-HMG1 antibody, or anti-p53 antibody were added to each tube and mixed. The mixture was incubated further for 2 h at 4 °C. Immunoprecipitates were washed three times with buffer containing 20 mm HEPES, pH 7.9, 120 mmNaCl, 1 mm EDTA, 1 mm EGTA, 1 mmphenylmethylsulfonyl fluoride, and 1 mm dithiothreitol followed by centrifugation. The immunoprecipitates mixed with 20 μl of sampling buffer were boiled for 5 min and subjected to SDS-polyacrylamide gel electrophoresis. The samples were transferred to polyvinylidene difluoride membranes, immunoblotted with anti-HMG1 antibody or anti-p53 antibody, and developed for visualization by chemiluminescence according to the ECL protocol (Amersham Pharmacia Biotech). GST fusion proteins and ThioHis fusion proteins were induced by isopropyl-1-thio-β-d-galactopyranoside as described previously (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). Cell extracts were treated with or without 75 units/ml DNaseI (Worthington, Lakewood, NJ) in pull-down buffer containing 1 mm CaCl2 at 37 °C for 1 h. GST fusion proteins binding to 15 μl of glutathione-Sepharose 4B in a 50% slurry were mixed with 0.5 mg of MCF-7 nuclear extract treated with 20 μm cisplatin for 24 h or ThioHis fusion proteins in binding buffer containing 50 mm Tris-HCl, pH 8.0, 1 mm EDTA, 120 mm NaCl, 10% glycerol, 0.5% Nonidet P-40, 1 mm dithiothreitol, and 0.5 mmphenylmethylsulfonyl fluoride. The mixtures were incubated for 2 h at 4 °C and washed three times with binding buffer. Pull-down samples representing 10% of input were electrophoresed and analyzed by immunoblotting by anti-Thio antibody as described above. Oligonucleotides of a 32-mer (5′-TCGGGGCGGGGCGATCGATCGGGGCGGGGCGA-3′) or a 63-mer (5′-CGCCCCCACCCTGCGCGCGCGATCCAAGGTTCTCACCTGGAGCGCTCAGGTAGGGCTGGGGCG-3′) were annealed with the complementary strands. Both single-stranded and double-stranded oligonucleotides were end-labeled with [γ-32P]ATP (Amersham Pharmacia Biotech), and purified from the gel. Half of each labeled oligonucleotides was treated with 0.3 mm cisplatin at 37 °C for 12 h and then was purified by ethanol precipitation. Numbers of platinum atoms bound to oligonucleotides (32-mer) were determined by atomic absorption spectroscopy (polarized Zeeman atomic absorption spectrophotometer Z-8200; Hitachi). The mean amount of platinum bound to DNA was about 6.7 platinum atoms/oligonucleotide under our conditions. GST fusion proteins binding glutathione-Sepharose 4B were eluted with 50 mm Tris-HCl, pH 8.0, and 20 mm reduced glutathione according to the manufacturer's protocol (Amersham Pharmacia Biotech). GST fusion proteins were used directly for EMSA. Reaction mixtures contained 4 μl of 5× EMSA buffer (25% glycerol, 50 mm Tris-HCl, pH 7.5, 250 mm NaCl, 5 mm MgCl2, 0.5 mm EDTA, 5 mm dithiothreitol), 2 μl of bovine serum albumin (1 mg/ml), 32P-labeled probe DNA (4 ng), GST fusion protein, and antibodies as indicated, and water in a total volume of 20 μl. Binding reactions were incubated for 5 min at room temperature. Products were analyzed on 4% polyacrylamide gels in 0.5× Tris borate EDTA buffer followed by BAS 2000 (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). HMG1 has been shown to interact directly with p53 to enhance p53 DNA binding in vitro (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). We initially examined the spectrum of nuclear proteins bound to a GST protein fused to either HMG1 or p53 using MCF-7 cells.35S-Labeled nuclear extracts prepared from MCF-7 cells treated with or without cisplatin were incubated with GST fusion proteins immmobilized on glutathione-Sepharose. A comparison of the profile of proteins bound to the GST fusion proteins is shown in Fig.1 A (left panel). A 53-kDa protein likely to correspond to p53 was observed by pull-down with GST-HMG1. On the other hand, a 28-kDa protein likely to correspond to HMG1 was observed by pull-down with GST-p53. No significant difference of protein profile was seen between MCF-7 cells treated with cisplatin and those treated without cisplatin. To determine whether these proteins respond to treatment with cisplatin, extracts from nuclei and were prepared from growing MCF-7 cells and analyzed by in 1 panel). cells were treated with cisplatin, p53 was Both HMG1 and p53 were in a nuclear transcription change in amount after cisplatin Sp1 not be in the that the fraction was not with nuclear protein. of wild type of p53 was high in MCF-7 cells. MCF-7 cells were treated with cisplatin for 24 nuclear levels of p53 with MCF-7 cells. of HMG1 and p53 were at lines, but in of p53 cisplatin treatment significantly levels of HMG1. To the of p53 with was using either or anti-p53 antibodies with MCF-7 cells treated with cisplatin. that p53 with HMG1 and the interaction of HMG1 with p53 was 1 To further this we a pull-down assay using GST fusion proteins and nuclear of the bound nuclear proteins that p53 with HMG1 but not with GST 1 box-binding protein 1 also has been found to interact with p53 T. Izumi H. Imamura T. Takano H. T. Uchiumi T. Kuwano M. Kohno K. PubMed Scopus Google Scholar) 1 We the domain of the HMG protein required for interaction with p53 by a pull-down assay using GST fusion proteins containing deletion mutants of HMG1 and ThioHis fusion proteins with p53 GST fusion proteins were shown by protein the A box of HMG1 was to bind p53, whereas fusion protein lacking the B box of HMG1 binding 2 To the that p53 and HMG1 to a DNA, we also the fusion proteins after treatment with which DNA under the not shown in 2 an between HMG1 and p53 be fusion protein was that HMG1 with p53 directly and that the HMG A box of HMG1 was for interaction with p53. We the domain of p53 for interaction with using GST fusion proteins to ThioHis-p53 or deletion assay that the C-terminal of p53 in the interaction with HMG1 A containing amino acids in this of p53 is for the HMG1 can sequence-specific DNA binding of p53 (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). We examined the the influence of p53 on DNA binding of HMG1 is to bind preferentially to cisplatin-modified DNA (7Pil P.M. Lippard S.J. Science. 1992; 256: 234-237Crossref PubMed Scopus (512) Google Scholar). We previously have shown that HMG1 bind to cisplatin-modified oligonucleotides of a to 20 pairs (10Ise T. Nagatani G. Imamura T. Kato K. Takano H. Nomoto M. Izumi H. Ohmori H. Okamoto T. Ohga T. Uchiumi T. Kuwano M. Kohno K. Cancer Res. 1999; 59: 342-346PubMed Google Scholar). We prepared oligonucleotides of a 32-mer and a and examined HMG1 binding. shown in a with was the 32-mer was modified with cisplatin, whereas were observed with the cisplatin-modified These that the 32-mer is for binding of whereas with the the to of HMG1 We therefore used the 32-mer for the we analyzed the activity of GST fusion protein using synthetic oligonucleotides with or without cisplatin shown in 4 HMG1 and can significantly bind to double-stranded oligonucleotides modified with cisplatin but not to single-stranded On the other hand, p53 not bind to these We examined the effect of p53 on cisplatin-modified DNA binding of HMG1 by EMSA Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53 in a 5 To HMG1 in the we the HMG1 protein and examined the effect of p53 on DNA binding of the was not by the concentration of HMG1. our addition of p53 to the binding reaction in activation of the DNA binding activity of HMG1. p53, which interact with was to DNA binding by HMG1 or GST p53 not the electrophoretic mobility of the HMG1 with cisplatin-modified DNA, and not be by the anti-p53 antibody not we found that HMG1-specific antibody also formation of the cisplatin-modified DNA HMG1 but or antibody not 5 panel). of anti-HMG1 antibody not formation of was the HMG1 antibody is not in of anti-HMG1 antibody to the binding reaction in a further shift in mobility 5 of binding to cisplatin-modified DNA by p53 or anti-HMG1 effect of p53 protein on cisplatin-modified DNA binding by HMG1 protein. of purified GST-HMG1 bound cisplatin-modified oligonucleotides in the of purified GST-p53 were analyzed by effect of deletion of p53 protein on cisplatin-modified DNA binding by HMG1 protein. 10 of purified GST-HMG1 bound cisplatin-modified oligonucleotides in the of either purified 160C, or were analyzed by EMSA. GST was used as a effect of anti-HMG1 antibody on cisplatin-modified DNA binding by HMG1 protein. 10 of purified or bound cisplatin-modified oligonucleotides in the of of antibodies were analyzed by EMSA 1, rabbit anti-HMG1 anti-p53 The effect of antibody on DNA binding of HMG1 is shown in the 1, of 20 of of of and of We that p53 directly interacts with HMG1 in cell extracts and in cells to enhance the cisplatin-modified DNA binding activity of HMG1. Both HMG1 and HMG2 are nonhistone chromosomal proteins that are and in eukaryotic cells R. K. J. Full Text PDF PubMed Scopus Google Scholar). the of these proteins is not an in and DNA DNA and The of the HMG box is a domain of about 70 amino acids that three amino The HMG A box and the HMG B box are about in amino acid A at 37 is for binding to cisplatin-modified oligonucleotides Lippard S.J. 1999; PubMed Scopus Google Scholar). is in the HMG B the HMG boxes are not in DNA binding. our the HMG A box can bind to cisplatin-modified DNA, whereas the HMG B box the under which EMSA is can influence the our result is with the that the HMG1 A box has a higher than the HMG1 B box for cisplatin-modified DNA Lippard S.J. 1997; PubMed Scopus Google Scholar). the HMG A box has been to be involved in DNA whereas the B box may be a for interactions M. J. 1999; PubMed Scopus Google Scholar). from that the HMG A box is involved in p53 but the HMG B box is The of p53 binding of the HMG B box may a difference in protein between this and the HMG A box. Interaction between the HMG1 A box and p53 required amino acids 363–376 of p53. of the of p53 is and to with cellular The HMG A box also is that interaction is not of a of interactions is by the that DNA binding by HMG1 also is enhanced by addition of anti-HMG1 antibody 5 of the domain in the interaction that the of DNA binding and the binding of be cells p53 protein in a that can be by DNA of the C-terminal domain of p53 have been shown to be in DNA binding as antibody and Lane Cell. 1992; Full Text PDF PubMed Scopus Google F. J. Chem. Full Text Full Text PDF PubMed Scopus Google W. Cell. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). HMG1 has been shown to significantly the sequence-specific DNA binding of p53 (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). peptides from the domain can the sequence-specific DNA binding of p53 A. Lane Cell. Full Text PDF PubMed Scopus Google Scholar). In the we found that the C-terminal domain of p53 is involved in HMG protein binding Interaction of HMG1 with p53 may be by the of p53. HMG proteins have been further shown to enhance the sequence-specific DNA binding of a variety of transcription factors as Bustin M. 1997; PubMed Scopus Google P. M. R. Cell. PubMed Google Scholar), proteins L. F. J. 1996; 15: PubMed Scopus Google Scholar), factors H. T. J. PubMed Scopus Google Scholar), and p53, as a coactivator for transcription of genes (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). has been reported to whether cisplatin-modified DNA binding activity of HMG proteins is by these cellular we examined whether damaged DNA binding of HMG1 was by interaction with p53. is the to that p53 the cisplatin-modified DNA binding of HMG1. was observed p53, which can bind to was added in an EMSA The mobility of HMG1 with cisplatin-modified DNA was not by p53, and HMG1 DNA not be by the addition of the anti-p53 antibody, Binding to HMG1 may the binding of p53 antibody the of p53 is the is that this interaction is and p53 may from the electrophoresis. can be enhanced and by the addition of antibody which that either antibody or p53 may induce the conformational change in the HMG1 A box that optimizes interaction with cisplatin-modified DNA. On the other hand, HMG1 can DNA binding by which the C-terminal amino acids (4Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (282) Google Scholar). is for interaction with that DNA binding of p53 is of interaction between p53 and HMG1. change of DNA by HMG1 has been to and p53 DNA that HMG1 is a protein J. K. J. 1998; 12: PubMed Scopus Google Scholar). of damage proteins have been that bind preferentially to damaged HMG transcription factors, and histones (7Pil P.M. Lippard S.J. Science. 1992; 256: 234-237Crossref PubMed Scopus (512) Google Scholar). Both the p53 protein and a damage protein bind at of DNA damage and repair. In this of whether other damage proteins can interact directly with p53 is The p53 protein not DNA as single-stranded DNA J. K. J. 1998; 12: PubMed Scopus Google Scholar) and DNA G. E. M. G. Res. 1996; PubMed Scopus Google Scholar) but also 3′ to 5′ exonuclease activity (3Mummenbrauer T. Janus F. Müller B. Wiesmüller L. Deppert W. Grosse F. Cell. 1996; 85: 1089-1099Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar). p53 protein after DNA damage be with in a DNA repair p53 can with a of proteins involved in repair. Thus, interaction of p53 with HMG proteins may have an in DNA repair. of HMG1 in to the have been shown to MCF-7 cells to cisplatin and Lippard S.J. A. PubMed Scopus Google Scholar). HMG1 is up-regulated in cisplatin-resistant cell not These that HMG proteins be in the cellular of cisplatin. is to the of HMG1 in cisplatin

References

25